Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Operating Expenses (2024 - 2025)

Kairos Pharma's Operating Expenses history spans 2 years, with the latest figure at $1.5 million for Q2 2025.

  • For Q2 2025, Operating Expenses rose 555.86% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.2 million, up 78.27%, while the annual FY2025 figure was $5.6 million, 137.81% up from the prior year.
  • Operating Expenses reached $1.5 million in Q2 2025 per KAPA's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.5 million in Q2 2025 to a low of $222000.0 in Q2 2024.